Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Losartan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Losartan. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-002995-17 Sponsor Protocol Number: 35820 Start Date*: 2011-08-15
    Sponsor Name:
    Full Title: Treatment trial of stiff skin syndrome with Losartan
    Medical condition: Stiff skin syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000869-38 Sponsor Protocol Number: VGSKAS-12916 Start Date*: 2008-06-02
    Sponsor Name:Skaraborg Hospital
    Full Title: Impact of Losartan in hypertensive men with obstructive sleep apnea
    Medical condition: Hypertension and obstructive sleep apnea (OSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016139-36 Sponsor Protocol Number: V1,11.05.2009 Start Date*: 2009-12-28
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Kinder-und Jugendheilkunde
    Full Title: The AT1 receptor antagonist losartan for the prevention of excessive aortic root dilatation in children and adolescents with Marfan syndrom
    Medical condition: Marfan-Syndrom
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000856-34 Sponsor Protocol Number: CSPP100A2316 Start Date*: 2005-08-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ve...
    Medical condition: left ventricular hypertrophy in overweight patients with essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002091-41 Sponsor Protocol Number: 03618 Start Date*: 2014-10-09
    Sponsor Name:Academisch medisch centrum
    Full Title: Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system
    Medical condition: To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001766-11 Sponsor Protocol Number: 2020-24 Start Date*: 2020-04-29
    Sponsor Name:ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE
    Full Title: Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit
    Medical condition: Patients with Covid-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003641-15 Sponsor Protocol Number: 2625 Start Date*: 2013-07-04
    Sponsor Name:North Bristol NHS Trust
    Full Title: Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting. The RADAR Trial. A phase II, two arm, double-blind, placebo-controlled, randomised trial to evaluate the effect of losartan ...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003647-28 Sponsor Protocol Number: NA Start Date*: 2020-12-09
    Sponsor Name:
    Full Title: Differences in antihypertensive drug levels in patients with hypertension: old vs young 2
    Medical condition: Hypertension Cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000690-34 Sponsor Protocol Number: 0954A-327 Start Date*: 2007-05-29
    Sponsor Name:Merck Sharp & Dohme OÜ
    Full Title: A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With ...
    Medical condition: Essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) FI (Prematurely Ended) LT (Prematurely Ended) HU (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006415-74 Sponsor Protocol Number: 0954-326 Start Date*: 2007-05-24
    Sponsor Name:MSD (Norge) AS
    Full Title: A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension
    Medical condition: Proteinuria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037032 Proteinuria LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed) LT (Completed) HU (Completed) ES (Completed) GB (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016735-36 Sponsor Protocol Number: CSPP100AES02 Start Date*: 2010-03-22
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio de los efectos de ALiskiren o Losartán sobre los bioMARKadores del remodelado miocárdico. Estudio ALLMARK
    Medical condition: HIPERTENSIÓN ARTERIAL ESENCIAL Y HIPERTROFIA VENTRICULAR IZQUIERDA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003542-68 Sponsor Protocol Number: Start Date*: 2016-01-27
    Sponsor Name:University of Oxford
    Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial
    Medical condition: DSM panic disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003670-32 Sponsor Protocol Number: REFLECT Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)
    Medical condition: Recessive dystrophic epidermolysis bullosa (RDEB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001191-12 Sponsor Protocol Number: Salt og Cirrhose Start Date*: 2005-07-06
    Sponsor Name:Odense Universitetshospital
    Full Title: Forebyggelse af inkompenseret levercirrose med Losartan Et prospektivt randomiseret dobbeltblindet lantidsstudie
    Medical condition: Alkoholisk levercirrose. Fibrosedannelse og senere cirrose i leveren efter en årrække med øget indtag/misbrug af alkohol. Komplikationer ses i form af inkomensation med ascites, oesofagusvaricer og...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015166-62 Sponsor Protocol Number: EME-08/43/15 Start Date*: 2010-11-16
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised controlled trial of Losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
    Medical condition: Fibrosis in patients with non-alcoholic steatohepatitis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005862-10 Sponsor Protocol Number: AGO/2007/011 Start Date*: 2009-05-29
    Sponsor Name:University Hospital Ghent
    Full Title: Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.
    Medical condition: Marfan syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026829 Marfan's syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003141-15 Sponsor Protocol Number: DC2019RECOLAR01 Start Date*: 2020-09-15
    Sponsor Name:Amsterdam University Medical Center - location VU Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with e...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001462-81 Sponsor Protocol Number: FARM7KP2PX Start Date*: 2008-10-27
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations
    Medical condition: Marfan Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026829 Marfan's syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018880-41 Sponsor Protocol Number: CARDPED-2010-01 Start Date*: 2010-06-01
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: EFFECTS OF LOSARTAN ON AORTIC ROOT AND ASCENDING AORTA REMODELING IN PATIENTS WITH BICUSPID AORTIC VALVE.
    Medical condition: PATIENTS WITH BICUSPID AORTIC VALVE.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004552 Bicuspid aortic valve LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-001125-97 Sponsor Protocol Number: LO-AT-MARFAN Start Date*: 2008-05-20
    Sponsor Name:alberto forteza
    Full Title: Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security...
    Medical condition: The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026829 Marfan's syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:19:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA